Literature DB >> 8904625

Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.

H J Marshall1, D G Beevers.   

Abstract

There have been occasional reports of female stress incontinence related to prazosin therapy for hypertension. This drug is now rarely used but recently longer acting alpha-adrenoceptor blocking drugs have been introduced. We have, therefore, investigated the prevalence of urinary incontinence in all our female patients who were receiving alpha-adrenoceptor blockers in comparison with women, matched for age and parity who were receiving other drugs. We identified a total of 49 women taking alpha-adrenoceptor blocking drugs (prazosin 4, terazosin 5, doxazosin 40) among current patients who were attending our hypertension clinic. Twenty of these (40.8%) reported some urinary incontinence whereas in the control patients, only 8 (16.3%) had this symptom (P = < 0.02, relative risk 2.5, 95% CI 1.22-5.13). alpha-Adrenoceptor blockers were withdrawn in 18 of the 20 patients with incontinence and in 13, their symptoms abated. Our results suggest that there is a significantly higher prevalence of urinary incontinence in women taking alpha-adrenoceptor antagonists with reversibility on withdrawal of these drugs. As both female urinary incontinence, hypertension and the use of alpha-adrenoceptor blocking drugs are common, this distressing side effect should be borne in mind so that gynaecological or urological treatment may be avoided in some women.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904625      PMCID: PMC2042702          DOI: 10.1046/j.1365-2125.1996.45217.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  The Problem of Polypharmacy in Female Patients with Overactive Bladders - Cross-Sectional Study in a Specialist Outpatient Department.

Authors:  C S Schneidinger; W Umek; B Böhmdorfer
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-12       Impact factor: 2.915

3.  The effect of medication use on urinary incontinence in community-dwelling elderly women.

Authors:  Christine M Ruby; Joseph T Hanlon; Robert M Boudreau; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Neil M Resnick
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

4.  Health information and interaction on the internet: a survey of female urinary incontinence.

Authors:  H Sandvik
Journal:  BMJ       Date:  1999-07-03

5.  Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women.

Authors:  Emily P Peron; Yan Zheng; Subashan Perera; Anne B Newman; Neil M Resnick; Ronald I Shorr; Douglas C Bauer; Eleanor M Simonsick; Shelly L Gray; Joseph T Hanlon; Christine M Ruby
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-09-12       Impact factor: 6.053

6.  An interesting case of an antihypertensive causing post-prostatectomy incontinence.

Authors:  Debashis Sarkar; Manal Kumar
Journal:  BMJ Case Rep       Date:  2015-09-30

7.  Urinary incontinence status and risk factors in women aged 50-70 years: a cross-sectional study in Hunan, China.

Authors:  Chen Xu; Mingzhu Chen; Jingxia Fu; Yanting Meng; Si Qin; Yang Luo
Journal:  Int Urogynecol J       Date:  2020-02-24       Impact factor: 2.894

Review 8.  Drug-induced urinary incontinence.

Authors:  Peter Tsakiris; Matthias Oelke; Martin C Michel
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 10.  Alpha1-adrenergic blockers: current usage considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.